Unknown

Dataset Information

Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer.


ABSTRACT:

Objective

Precision oncology depends on translating molecular data into therapy recommendations. However, with the growing complexity of next-generation sequencing-based tests, clinical interpretation of somatic genomic mutations has evolved into a formidable task. Here, we compared the performance of three commercial clinical decision support tools, that is, NAVIFY Mutation Profiler (NAVIFY; Roche), QIAGEN Clinical Insight (QCI) Interpret (QIAGEN) and CureMatch Bionov (CureMatch).

Methods

In order to obtain the current status of the respective tumour genome, we analysed cell-free DNA from patients with metastatic breast, colorectal or non-small cell lung cancer. We evaluated somatic copy number alterations and in parallel applied a 77-gene panel (AVENIO ctDNA Expanded Panel

SUBMITTER: Perakis SO 

PROVIDER: S-EPMC7513637 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature